SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · BridgeBio announced additional positive data from the Phase 3 PROPEL 3…

BridgeBio Pharma, Inc. · PRESS-RELEASE filed Jun 22, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Jun 22, 2026 at 07:30 ET

BridgeBio announced additional positive data from the Phase 3 PROPEL 3 study of oral infigratinib in achondroplasia will be presented at ICCBH 2026, alongside other skeletal dysplasia and ADH1 data. This is a routine pipeline update with no new regulatory or commercial catalyst, the data was previously disclosed and the presentation is a conference update, not a new approval or trial result.

  • Positive data from PROPEL 3 Phase 3 study of oral infigratinib in achondroplasia to be presented in late-breaking oral at ICCBH 2026 on June 28.
  • Additional presentations include quality-of-life findings from PROPEL observational study, Phase 2/2b design for children under 3, and ADH1 CLARIFY study poster.
  • No new regulatory filing, approval, or commercial milestone announced, this is a conference data presentation update.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access